Public Outcry Follows Gilead Decision to Charge $3000 for COVID Drug that Costs Pennies to Produce
California-based pharmaceutical giant Gilead Sciences has announced that a five-day course of its antiviral drug Remdesivir — shown in tests to effectively fight COVID-19 — will cost $3,120 to Americans with health insurance and $2,340 to those on Medicaid.
